Four global shops are vying to handle ad duties outside the U.S. for a new urinary-incontinence drug from Eli Lilly & Co. and Boehringer Ingelheim, sources said. The finalists for the estimated $25 million account are WPP’s J. Walter Thompson, London; Omnicom’s BBDO, Dusseldorf, Germany; Interpublic’s Foote, Cone & Belding, New York; and Havas’ Euro RSCG Life, London, sources said. Final pitches are scheduled for mid-October at Boehringer Ingelheim’s headquarters in Ingelheim, Germany, said sources. The agencies either declined comment or could not be reached.
Get Adweek's Brand Marketing Daily Newsletter in your Inbox
Today's highs and lows of creativity